BioXcel Therapeutics, Inc.
$1.2
▼
-3.28%
2026-04-21 05:48:00
www.bioxceltherapeutics.com
NCM: BTAI
Explore BioXcel Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$32.49 M
Current Price
$1.2
52W High / Low
$8.08 / $1.01
Stock P/E
—
Book Value
$-4.28
Dividend Yield
—
ROCE
557.9%
ROE
74.14%
Face Value
—
EPS
$-5.73
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
29
Beta
0.3
Debt / Equity
-1.15
Current Ratio
0.83
Quick Ratio
0.82
Forward P/E
-0.64
Price / Sales
44.7
Enterprise Value
$109.94 M
EV / EBITDA
-2.2
EV / Revenue
171.25
Rating
Buy
Target Price
$14
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Elanco Animal Health Incorporated | $22.34 | — | $11.2 B | — | 2.14% | -3.67% | $27.72 / $8.02 | $13.17 |
| 2. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 3. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 4. | Caring Brands, Inc. | $1.25 | — | — | — | -157.44% | -2.17% | $6 / $0.06 | $0.14 |
| 5. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 6. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
| 7. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.26 M | 0.1 M | 0.12 M | 0.17 M | 0.37 M | — |
| Operating Profit | -10.28 M | -14.03 M | -15.85 M | -10.1 M | -10.46 M | — |
| Net Profit | -12.54 M | -30.91 M | -19.19 M | -7.25 M | -10.86 M | — |
| EPS in Rs | -0.46 | -1.14 | -0.71 | -0.27 | -0.4 | -5.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.64 M | 2.27 M | 1.38 M | 0.38 M |
| Operating Profit | -50.27 M | -64.8 M | -167.62 M | -159.65 M |
| Net Profit | -69.9 M | -59.6 M | -179.05 M | -165.76 M |
| EPS in Rs | -2.58 | -2.2 | -6.61 | -6.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 44.92 M | 38.34 M | 73.7 M | 205.85 M |
| Total Liabilities | 140.38 M | 131.44 M | 130.21 M | 129.08 M |
| Equity | -95.46 M | -93.1 M | -56.51 M | 76.78 M |
| Current Assets | 44.69 M | 37.39 M | 72.14 M | 202.87 M |
| Current Liabilities | 53.93 M | 22.23 M | 27.27 M | 32.9 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -57.62 M | -72.03 M | -155.01 M | -135.34 M |
| Investing CF | 0 M | 0 M | -0.02 M | -0.14 M |
| Financing CF | 56.52 M | 36.66 M | 26.52 M | 96.24 M |
| Free CF | -57.62 M | -72.03 M | -155.03 M | -135.48 M |
| Capex | — | — | -0.02 M | -0.14 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -71.67% | 64.2% | 268% | — |
| Earnings Growth % | -17.28% | 66.71% | -8.02% | — |
| Profit Margin % | -10887.38% | -2630.14% | -12974.86% | -44201.87% |
| Operating Margin % | -7829.75% | -2859.84% | -12146.3% | -42572% |
| Gross Margin % | 74.45% | 5.43% | 8.7% | 94.67% |
| EBITDA Margin % | -8195.17% | -1948.85% | -11987.03% | -41924.53% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-02-10 | 1:0.0625 |